Firm Wire items are announcements made by the firms themselves. The desk confirms that the announcement was published and reproduces its factual content. It does not verify the claims in it, and publication is not an endorsement.
Sidley says it advised Aquestive on Libervant licensing and supply agreements
Sidley said it represented Aquestive Therapeutics in licensing and supply agreements with Eton Pharmaceuticals for Libervant, a diazepam buccal film for seizure clusters in patients with epilepsy. The firm said Eton received exclusive commercialization rights in the United States and its territories.
Key points
- Sidley described Libervant as an orphan-designated treatment.Sidley
- The firm cited an estimated U.S. market exceeding $450 million annually.Sidley
- Sidley said commercial launch is anticipated in April 2027, subject to final FDA approval.Sidley
- The firm said Jennifer Raab led its team, with Yuhan Wu, Jonathan Trang and Steven Przesmicki.Sidley